Compare Solaredge Technologies Inc (SEDG) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Solaredge Technologies Inc vs Sanofi SA — how do they compare? Solaredge Technologies Inc trades at $32.12 (market cap $2.05B), while Sanofi SA trades at $43.6 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 50.9× Solaredge Technologies Inc's market cap, and Sanofi SA pays a 5.55% dividend while Solaredge Technologies Inc pays none. Which is the better fit depends on your goals.
| SEDG | SNY | |
|---|---|---|
Market Cap | $2.05B | $104.30B |
Sector | Technology | Health |
52-Week High | $78.51 | $52.34 |
52-Week Low | $25.10 | $41.33 |
Enterprise Value | $1.91B | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SolarEdge Technologies (SEDG) trades at $32.04, down 0.53% on the day, reflecting ongoing volatility amid mixed financial performance. The stock exhibits a bearish technical trend, with negative profitability metrics including a net income margin of -20.29% and ROE of -58.42% for 2026. Recent Q2 2026 earnings beat expectations with EPS of $0.06, but weak Q3 revenue guidance has pressured shares. Cash flow improved in 2025 with net cash flow of $138.60 million, though debt levels remain elevated.
The outlook is cautious due to persistent losses, high dependence on policy incentives, and a challenging U.S. residential solar market. Analyst consensus is mixed with a hold-heavy rating (58.34%) and a $35.15 price target, suggesting limited near-term upside. Key risks include execution missteps, competitive pressures, and macroeconomic headwinds, requiring careful monitoring of margin recovery and demand trends.
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
